Cargando…
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome...
Autores principales: | Lyngbakken, Magnus Nakrem, Berdal, Jan-Erik, Eskesen, Arne, Kvale, Dag, Olsen, Inge Christoffer, Rueegg, Corina Silvia, Rangberg, Anbjørg, Jonassen, Christine Monceyron, Omland, Torbjørn, Røsjø, Helge, Dalgard, Olav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576792/ https://www.ncbi.nlm.nih.gov/pubmed/33082342 http://dx.doi.org/10.1038/s41467-020-19056-6 |
Ejemplares similares
-
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial
por: Lyngbakken, Magnus Nakrem, et al.
Publicado: (2020) -
Subclinical Myocardial Injury and Risk of COVID-19 in the General Population: The Trøndelag Health Study
por: Lyngbakken, Magnus Nakrem, et al.
Publicado: (2021) -
Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19
por: Myhre, Peder L., et al.
Publicado: (2020) -
Tobacco Consumption and High‐Sensitivity Cardiac Troponin I in the General Population: The HUNT Study
por: Skranes, Julia Brox, et al.
Publicado: (2022) -
Prognostic value of cardiac biomarkers and National Early Warning Score 2 in acute dyspnoea
por: Berge, Kristian, et al.
Publicado: (2022)